Engaging global payers for better trial design

engaging global payers

A clinical team wanted to design a Phase III trial for a new therapy used to treat a rare disease. To gauge economic viability, the team needed to understand how global payer organizations would weigh the benefits of the therapy and where the treatment might be placed in formularies.